{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T02:17:33Z","timestamp":1784600253659,"version":"3.55.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ejso.2025.110356","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T06:09:05Z","timestamp":1753682945000},"page":"110356","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Oncological outcomes of sentinel lymph node biopsy alone in patients with residual nodal disease after neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"51","author":[{"given":"A.M.","family":"Zaborowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"McGarry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Wehrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.J.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Rothwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.L.","family":"Rutherford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Evoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"McCartan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.S.","family":"Prichard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.R.","family":"Boland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ejso.2025.110356_bib1","doi-asserted-by":"crossref","DOI":"10.1001\/jamasurg.2021.0891","article-title":"Axillary pathologic complete response after neoadjuvant systemic therapy by breast cancer subtype in patients with initially clinically node-positive disease: a systematic review and meta-analysis","volume":"156","author":"Samiei","year":"2021","journal-title":"JAMA Surg"},{"issue":"10","key":"10.1016\/j.ejso.2025.110356_bib2","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.annonc.2021.06.023","article-title":"Customizing local and systemic therapies for women with early breast cancer: the St. Gallen international consensus guidelines for treatment of early breast cancer 2021","volume":"32","author":"Burstein","year":"2021","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.ejso.2025.110356_bib3","doi-asserted-by":"crossref","first-page":"7362","DOI":"10.1245\/s10434-024-15705-y","article-title":"Contemporary axillary surgical management in patients with pathologically node positive disease after neoadjuvant chemotherapy: a survey of members of the American society of breast surgeons","volume":"31","author":"Weiss","year":"2024","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"10.1016\/j.ejso.2025.110356_bib4","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/jama.2017.11470","article-title":"Effect of axillary dissection vs No axillary dissection on 10-Year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial","volume":"318","author":"Giuliano","year":"2017","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.ejso.2025.110356_bib5","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1200\/JCO.22.01565","article-title":"Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer: 10-year results of the randomized controlled EORTC 10981-22023 AMAROS trial","volume":"41","author":"Bartels","year":"2023","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ejso.2025.110356_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"issue":"7","key":"10.1016\/j.ejso.2025.110356_bib7","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1245\/s10434-018-6486-6","article-title":"Eighth edition of the AJCC cancer staging manual: breast cancer","volume":"25","author":"Giuliano","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"10.1016\/j.ejso.2025.110356_bib8","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"issue":"9","key":"10.1016\/j.ejso.2025.110356_bib9","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non-randomized studies (minors): development and validation of a new instrument","volume":"73","author":"Slim","year":"2003","journal-title":"ANZ J Surg"},{"issue":"2","key":"10.1016\/j.ejso.2025.110356_bib10","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1245\/s10434-020-08928-2","article-title":"Omission of axillary lymph node dissection is associated with inferior survival in breast cancer patients with residual N1 nodal disease following neoadjuvant chemotherapy","volume":"28","author":"Almahariq","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"13","key":"10.1016\/j.ejso.2025.110356_bib11","doi-asserted-by":"crossref","first-page":"8371","DOI":"10.1245\/s10434-023-14029-7","article-title":"Surgical management of the axilla in HR+\/HER2- breast cancer in the Z1071 era: a propensity score-matched analysis of the national cancer database","volume":"30","author":"Barker","year":"2023","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"10.1016\/j.ejso.2025.110356_bib12","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1016\/j.ejso.2021.06.024","article-title":"Favorable outcome with sentinel lymph node biopsy alone after neoadjuvant chemotherapy in clinically node positive breast cancer at diagnosis: Turkish multicentric NEOSENTI-TURK MF-18-02-study","volume":"47","author":"Cab\u0131o\u011flu","year":"2021","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2025.110356_bib13","doi-asserted-by":"crossref","first-page":"9056","DOI":"10.1038\/s41598-021-88442-x","article-title":"Sentinel node biopsy alone for breast cancer patients with residual nodal disease after neoadjuvant chemotherapy","volume":"11","author":"Chun","year":"2021","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.ejso.2025.110356_bib14","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.clbc.2020.04.008","article-title":"Patterns of failure in women who have residual nodal disease after neoadjuvant chemotherapy for breast cancer according to extent of lymph node surgery","volume":"20","author":"Kozak","year":"2020","journal-title":"Clin Breast Cancer"},{"issue":"2","key":"10.1016\/j.ejso.2025.110356_bib15","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.adro.2019.09.006","article-title":"Regional recurrence rates with or without complete axillary dissection for breast cancer patients with node-positive disease on sentinel lymph node biopsy after neoadjuvant chemotherapy","volume":"5","author":"Ling","year":"2020","journal-title":"Adv Radiat Oncol"},{"issue":"13","key":"10.1016\/j.ejso.2025.110356_bib16","doi-asserted-by":"crossref","first-page":"8813","DOI":"10.1245\/s10434-024-16143-6","article-title":"Omission of axillary lymph node dissection in patients with residual nodal disease after neoadjuvant chemotherapy","volume":"31","author":"Limberg","year":"2024","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2025.110356_bib17","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ejso.2022.11.099","article-title":"Omission of axillary lymph node dissection in patients with ypN+ breast cancer after neoadjuvant chemotherapy: a retrospective multicenter study (KROG 21-06)","volume":"49","author":"Park","year":"2023","journal-title":"Eur J Surg Oncol"},{"issue":"5","key":"10.1016\/j.ejso.2025.110356_bib18","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1245\/s10434-020-09211-0","article-title":"Oncologic safety of sentinel lymph node biopsy alone after neoadjuvant chemotherapy for breast cancer","volume":"28","author":"Wong","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"10.1016\/j.ejso.2025.110356_bib19","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1470-2045(13)70166-9","article-title":"Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study","volume":"14","author":"Kuehn","year":"2013","journal-title":"Lancet Oncol"},{"issue":"14","key":"10.1016\/j.ejso.2025.110356_bib20","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1001\/jama.2013.278932","article-title":"Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial","volume":"310","author":"Boughey","year":"2013","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.ejso.2025.110356_bib21","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1200\/JCO.2014.55.7827","article-title":"Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study","volume":"33","author":"Boileau","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2025.110356_bib22","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jss.2023.08.004","article-title":"Omission of axillary dissection in node positive breast cancer after neoadjuvant systemic therapy","volume":"292","author":"Peery","year":"2023","journal-title":"J Surg Res"},{"issue":"11","key":"10.1016\/j.ejso.2025.110356_bib23","doi-asserted-by":"crossref","first-page":"6401","DOI":"10.1245\/s10434-023-13759-y","article-title":"Changes in surgical management of the axilla over 11 years - report on more than 1500 breast cancer patients treated with neoadjuvant chemotherapy on the prospective I-SPY2 trial","volume":"30","author":"Boughey","year":"2023","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"10.1016\/j.ejso.2025.110356_bib24","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1245\/s10434-019-07583-6","article-title":"Surgical management of the axilla in clinically node-positive patients receiving neoadjuvant chemotherapy: a national cancer database analysis","volume":"26","author":"Wong","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.ejso.2025.110356_bib25","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1245\/s10434-018-6429-2","article-title":"Is low-volume disease in the sentinel node after neoadjuvant chemotherapy an indication for axillary dissection?","volume":"25","author":"Moo","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"10.1016\/j.ejso.2025.110356_bib26","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1245\/s10434-018-6578-3","article-title":"Predicting non-sentinel lymph node metastases in patients with a positive sentinel lymph node after neoadjuvant chemotherapy","volume":"25","author":"Barron","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"10.1016\/j.ejso.2025.110356_bib27","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.1245\/s10434-019-07517-2","article-title":"Prognostic significance of residual axillary nodal micrometastases and isolated tumor cells after neoadjuvant chemotherapy for breast cancer","volume":"26","author":"Wong","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"10.1016\/j.ejso.2025.110356_bib28","doi-asserted-by":"crossref","first-page":"7769","DOI":"10.1245\/s10434-022-12064-4","article-title":"Factors influencing non-sentinel lymph node involvement in patients with positive sentinel lymph node(s) after neoadjuvant chemotherapy for breast cancer","volume":"29","author":"Sanders","year":"2022","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"10.1016\/j.ejso.2025.110356_bib29","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1177\/00031348241248813","article-title":"Factors associated with additional axillary disease in patients with positive sentinel lymph nodes after neoadjuvant chemotherapy for breast cancer","volume":"90","author":"Johnson","year":"2024","journal-title":"Am Surg"},{"issue":"1","key":"10.1016\/j.ejso.2025.110356_bib30","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s10549-017-4157-0","article-title":"Prognosis of residual axillary disease after neoadjuvant chemotherapy in clinically node-positive breast cancer patients: isolated tumor cells and micrometastases carry a better prognosis than macrometastases","volume":"163","author":"van Nijnatten","year":"2017","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"10.1016\/j.ejso.2025.110356_bib31","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1200\/JCO.24.01052","article-title":"Nodal burden and oncologic outcomes in patients with residual isolated tumor cells after neoadjuvant chemotherapy (ypN0i+): the OPBC-05\/ICARO study","volume":"43","author":"Montagna","year":"2025","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ejso.2025.110356_bib32","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/S1470-2045(14)70460-7","article-title":"Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial","volume":"15","author":"Donker","year":"2014","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2025.110356_bib33","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1186\/s13063-018-3021-9","article-title":"Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trial","volume":"19","author":"Henke","year":"2018","journal-title":"Trials"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S074879832500784X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S074879832500784X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T19:40:29Z","timestamp":1759002029000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S074879832500784X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S074879832500784X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2025.110356","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oncological outcomes of sentinel lymph node biopsy alone in patients with residual nodal disease after neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2025.110356","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"110356"}}